Roche faces another delay in struggle to navigate Spark deal past regulators — but this one is very short
Roche today issued the latest in a long string of delays of its $4.3 billion buyout of Philadelphia-based Spark Therapeutics. The delay comes as little surprise — it is their 10th in as many months — as their most recent delay was scheduled to expire before a key regulatory deadline.
But it is notable for its length: 6 days.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.